<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="95557">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01860846</url>
  </required_header>
  <id_info>
    <org_study_id>P13-338</org_study_id>
    <nct_id>NCT01860846</nct_id>
  </id_info>
  <brief_title>Improvement of Work Productivity and Quality of Life With Anti-Tumor Necrosis Factor (TNF) Therapies Used in Crohn's Disease in Routine Clinical Practice in Turkey</brief_title>
  <acronym>IDEA</acronym>
  <official_title>Improvement of Work Productivity and Quality of Life With Anti-TNF Therapies Used in Crohn's Disease in Routine Clinical Practice in Turkey</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This post marketing observational study (PMOS) is designed to collect long-term data on the
      work productivity and changes in quality of life measurements with anti-Tumor Necrosis
      Factor therapies in patients with moderate to severe Crohn's disease whom are intolerant
      or/and unresponsive to conventional therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of Work Absenteeism</measure>
    <time_frame>12 months</time_frame>
    <description>To collect the number of missed working days and the number of working days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Work Productivity Impairment (TWPI)</measure>
    <time_frame>12 months</time_frame>
    <description>To collect Total Work Productivity Impairment by Total Work Productivity Impairment Scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Activity Impairment (TAI) scales</measure>
    <time_frame>12 months</time_frame>
    <description>To collect Total Activity Impairment by Total Activity Impairment Scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Average Short Form Health Survey-36 (SF-36) score change</measure>
    <time_frame>Day 0 to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Inflammatory Bowel Disease Questionnaire (IBDQ) score change</measure>
    <time_frame>Day 0 to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects with Serious Adverse Events</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">104</enrollment>
  <condition>Crohn's Disease</condition>
  <arm_group>
    <arm_group_label>Crohn's disease patients</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Crohn's disease patients who at time of entry are receiving anti-Tumor Necrosis Factors as
        it is prescribed in the normal clinical setting and according to approved Summary of
        Product Characteristics (SmPC) for this disease.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients between 18-65 years of age with moderately/severely (Crohn's
             Disease Activity Index 220-450) active Crohn's disease with/without fistula formation

          -  Patients who are able to provide authorization to use and disclose information
             related with the study

          -  Proven diagnosis of Crohn's Disease in accordance with international diagnostic
             criteria such as European Crohn's and Colitis Organisation (ECCO) guidelines

          -  Patients for whom the physician has initiated Crohn's disease treatment with
             anti-Tumor Necrosis Factors in accordance with Turkish Ministry of Health regulations
             and reimbursements.

        Exclusion Criteria:

          -  Subject has a history of any kind of biological therapy and/or anti-Tumor Necrosis
             Factor treatments for Crohn's disease or other indications

          -  Subject has septic complications (active infection and/or active Tuberculosis,
             undrained abscess)

          -  Patients who have bowel obstructions and fibrotic strictures

          -  Subject has received any investigational drug within 30 days prior to the Visit 1 at
             baseline

          -  For any reason, subject is considered by the investigator to be an unsuitable.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mahmut Gücük, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 62756</name>
      <address>
        <city>Ankara</city>
        <zip>6100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 67902</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 67904</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 67909</name>
      <address>
        <city>Bornova, Izmir</city>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 67905</name>
      <address>
        <city>Edirne</city>
        <zip>22031</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 67907</name>
      <address>
        <city>Istanbul</city>
        <zip>34093</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 67915</name>
      <address>
        <city>Istanbul</city>
        <zip>34098</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 93553</name>
      <address>
        <city>Istanbul</city>
        <zip>34349</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 67912</name>
      <address>
        <city>Istanbul</city>
        <zip>34899</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 67914</name>
      <address>
        <city>Izmir</city>
        <zip>35340</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 67913</name>
      <address>
        <city>Izmir</city>
        <zip>35360</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 93554</name>
      <address>
        <city>Kocaeli</city>
        <zip>41380</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 94495</name>
      <address>
        <city>Konya</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 67910</name>
      <address>
        <city>Mersin</city>
        <zip>4926</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 67906</name>
      <address>
        <city>Sıhhıye Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <link>
    <url>http://www.rxabbvie.com</url>
  </link>
  <verification_date>February 2016</verification_date>
  <lastchanged_date>February 17, 2016</lastchanged_date>
  <firstreceived_date>May 21, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Crohn's disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
